Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT03076970
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Unit, Baltimore, Maryland, United States
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT03073213
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳Second Affiliate Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China
🇨🇳Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 201
- Registration Number
- NCT03073200
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Modern Research Associates PLLC, Dallas, Texas, United States
🇲🇽Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: LY900014Drug: Insulin Lispro (Humalog)
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03056456
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Neuss, Germany
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: Mirikizumab TestBiological: Mirikizumab Reference
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 67
- Registration Number
- NCT03053622
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration
- Conditions
- Healthy
- Interventions
- Drug: [14C]-lasmiditan
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT03040362
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT03040479
- Locations
- 🇺🇸
NOCCR, Knoxville, Kentucky, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇨🇦Altasciences Company Inc./Algorithme Pharma, Mount-Royal, Quebec, Canada
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
- Conditions
- Solid TumorCholangiocarcinomaGall Bladder CarcinomaAdvanced CancerMetastatic CancerBiliary Tract CarcinomaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT03027284
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan
A Study of LY3192767 in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 57
- Registration Number
- NCT03025009
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Nordrhein-Westfalen, Germany
A Study of LY3202626 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3202626 (R-Fasting)Drug: LY3202626 (T1-Fasting)Drug: LY3202626 (T1-Fed)
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT03023826
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore